{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:25:20Z","timestamp":1792005920637,"version":"4.4.0"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Antimicrobial stewardship programs are important for reducing antimicrobial resistance because they can readjust antibiotic prescriptions to local guidelines, switch intravenous to oral administration, and reduce hospitalization times. Pharmacokinetics\u2013pharmacodynamics (PK-PD) empirically based prescriptions and therapeutic drug monitoring (TDM) programs are essential for antimicrobial stewardship, but there is a need to fit protocols according to cost benefits. The cost benefits can be demonstrated by reducing toxicity and hospital stay, decreasing the amount of drug used per day, and preventing relapses in infection. Our aim was to review the data available on whether PK-PD empirically based prescriptions and TDM could improve the cost benefits of an antimicrobial stewardship program to decrease global hospital expenditures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A narrative review based on PubMed search with the relevant studies of vancomycin, aminoglycosides, beta-lactams, and voriconazole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>TDM protocols demonstrated important cost benefit for patients treated with vancomycin, aminoglycosides, and voriconazole mainly due to reduce toxicities and decreasing the hospital length of stay. In addition, PK-PD strategies that used infusion modifications to meropenem, piperacillin-tazobactam, ceftazidime, and cefepime, such as extended or continuous infusion, demonstrated important cost benefits, mainly due to reducing daily drug needs and lengths of hospital stays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TDM protocols and PK-PD empirically based prescriptions improve the cost-benefits and decrease the global hospital expenditures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001067","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T13:11:46Z","timestamp":1673269906000},"page":"200-208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["Optimization of Antimicrobial Stewardship Programs Using Therapeutic Drug Monitoring and Pharmacokinetics\u2013Pharmacodynamics Protocols: A Cost-Benefit Review"],"prefix":"10.1097","volume":"45","author":[{"given":"Jo\u00e3o Paulo","family":"Telles","sequence":"first","affiliation":[{"name":"- AC Camargo Cancer Center, Infectious Diseases Department, S\u00e3o Paulo ;"},{"name":"- Laboratory of Emerging Infectious Diseases, Pontifical Catholic University of Paran\u00e1, Curitiba ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Morales","sequence":"additional","affiliation":[{"name":"- Clinical Pharmacokinetics Center, School of Pharmaceutical Sciences, University of S\u00e3o Paulo ;"},{"name":"- Pediatric Intensive Care Unit, Department of Pediatrics, Hospital S\u00edrio-Liban\u00eas. S\u00e3o Paulo ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Hikari","family":"Yamada","sequence":"additional","affiliation":[{"name":"- Laboratory of Emerging Infectious Diseases, Pontifical Catholic University of Paran\u00e1, Curitiba ;"},{"name":"- Hospital Universit\u00e1rio Evang\u00e9lico Mackenzie, Department of Infectious Diseases, Curitiba ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana A.","family":"Marins","sequence":"additional","affiliation":[{"name":"- Hospital Israelita Albert Einstein, Department of Clinical Pharmacy, S\u00e3o Paulo ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"D'Amaro Juodinis","sequence":"additional","affiliation":[{"name":"- Pediatric Intensive Care Unit, Department of Pediatrics, Hospital S\u00edrio-Liban\u00eas. S\u00e3o Paulo ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques","family":"Sztajnbok","sequence":"additional","affiliation":[{"name":"- Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo ;"},{"name":"- Instituto da Crian\u00e7a do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo (ICr\/HC-FMUSP);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moacyr","family":"Silva","sequence":"additional","affiliation":[{"name":"- Hospital Israelita Albert Einstein, Department of Infection Prevention and Control, S\u00e3o Paulo ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bil Randerson","family":"Bassetti","sequence":"additional","affiliation":[{"name":"- Hospital Santa Rita de C\u00e1ssia, Department of Infectious Disease and Infection Control, Vit\u00f3ria ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Albiero","sequence":"additional","affiliation":[{"name":"- Universidade Estadual de Maring\u00e1, Pharmacy Department, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Assist\u00eancia Farmac\u00eautica, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Francisco","family":"Tuon","sequence":"additional","affiliation":[{"name":"- Laboratory of Emerging Infectious Diseases, Pontifical Catholic University of Paran\u00e1, Curitiba ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhin.2019.03.002","article-title":"The economic impact of antimicrobial stewardship programmes in hospitals: a systematic literature review","volume":"102","author":"Huebner","year":"2019","journal-title":"J Hosp Infect."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjid.2020.05.005","article-title":"A broad-spectrum beta-lactam-sparing stewardship program in a middle-income country public hospital: antibiotic use and expenditure outcomes and antimicrobial susceptibility profiles","volume":"24","author":"Zequinao","year":"2020","journal-title":"Braz J Infect Dis."},{"key":"R3-20250603","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1346 e1","DOI":"10.1016\/j.cmi.2020.11.008","article-title":"Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/43.4.523","article-title":"Continuous infusion versus intermittent administration of meropenem in critically ill patients","volume":"43","author":"Thalhammer","year":"1999","journal-title":"J Antimicrob Chemother."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC-Antimicrobial Resist."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing.","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and pharmacokinetic outcomes of peak\u2013trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin Trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-System Pharm."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","article-title":"Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity","volume":"23","author":"Darko","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bjid.2020.07.001","article-title":"Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units","volume":"24","author":"Yamada","year":"2020","journal-title":"Braz J Infect Dis."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40262-017-0548-y","article-title":"Penetration of vancomycin into the cerebrospinal fluid: a systematic review","volume":"56","author":"Beach","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/FTD.0000000000000907","article-title":"Cerebrospinal fluid penetration of vancomycin during continuous infusion therapy in patients with nosocomial ventriculitis","volume":"43","author":"Tuon","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"625 e1","DOI":"10.1016\/j.eimc.2015.03.015","article-title":"Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/diagnostics12040845","article-title":"Different antimicrobial susceptibility testing methods to determine vancomycin susceptibility and MIC for Staphylococcus aureus with reduced vancomycin susceptibility","volume":"12","author":"Chung","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-8579(02)00030-4","article-title":"Extended interval aminoglycoside dosing: from concept to clinic","volume":"19","author":"Maglio","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/157.2.287","article-title":"In vivo postantibiotic effect in a thigh infection in neutropenic mice","volume":"157","author":"Vogelman","year":"1988","journal-title":"J Infect Dis."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/AAC.42.4.749","article-title":"Duration and clinical relevance of postantibiotic effect in relation to the dosing interval","volume":"42","author":"den Hollander","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.therap.2020.10.003","article-title":"Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: preliminary data from a prospective study","volume":"76","author":"Corcione","year":"2021","journal-title":"Therapies"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R32-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115239","article-title":"Distribution of genes encoding 16S rRNA methyltransferase in plazomicin-nonsusceptible carbapenemase-producing Enterobacterales in Brazil","volume":"99","author":"Bail","year":"2021","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2017.11.004","article-title":"Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers","volume":"90","author":"Martins","year":"2018","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","article-title":"An international survey on aminoglycoside practices in critically ill patients: the AMINO III study","volume":"11","author":"Roger","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jinf.2018.01.008","article-title":"Acute kidney injury in patients using low dose (3 mg\/kg\/day) of gentamicin under therapeutic dose monitoring","volume":"76","author":"Peixoto","year":"2018","journal-title":"J Infect."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00134-017-4755-7","article-title":"Acute kidney injury in sepsis","volume":"43","author":"Bellomo","year":"2017","journal-title":"Intensive Care Med."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","article-title":"Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A- TEAMICU survey","volume":"11","author":"Lanckohr","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R40-20250603","first-page":"443","article-title":"Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs","volume":"21","author":"Streetman","year":"2001","journal-title":"Pharmacother Official J Am Coll Clin Pharm."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring committee of the international association for therapeutic drug M, clinical toxicology. Cost-Effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jps.2600680304","article-title":"Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis","volume":"68","author":"Lyle Bootman","year":"1979","journal-title":"J Pharm Sci."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00019053-199814040-00005","article-title":"Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring","volume":"14","author":"Slaughter","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of beta-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d'Anesthesie et Reanimation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"R47-20250603","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.781892","article-title":"Impact of maximizing css\/MIC ratio on efficacy of continuous infusion meropenem against documented gram-negative infections in critically ill patients and population pharmacokinetic\/pharmacodynamic analysis to support treatment optimization","volume":"12","author":"Cojutti","year":"2021","journal-title":"Front Pharmacol."},{"key":"R48-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114900","article-title":"Evaluation of 4 quantification methods for monitoring 16 antibiotics and 1 beta-lactamase inhibitor in human serum by high-performance liquid chromatography with tandem mass spectrometry detection","volume":"219","author":"Seraissol","year":"2022","journal-title":"J Pharm Biomed Anal."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14787210.2020.1788387","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in the ICU","volume":"18","author":"Dhaese","year":"2020","journal-title":"Expert Rev Anti-infective Ther."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0000000000000891","article-title":"Health care costs of target attainment for beta-lactam antibiotics in critically ill patients: a retrospective analysis of the EXPAT study","volume":"44","author":"Ewoldt","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijantimicag.2010.01.018","article-title":"Daily serum piperacillin monitoring is advisable in critically ill patients","volume":"35","author":"Blondiaux","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FTD.0b013e31824981a6","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study","volume":"34","author":"Patel","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"e00654-17","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MAJ.0b013e31803195e7","article-title":"Piperacillin\/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis","volume":"333","author":"Lin","year":"2007","journal-title":"Am J Med Sci."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ajhp\/60.22.2321","article-title":"Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study","volume":"60","author":"Florea","year":"2003","journal-title":"Am J Health-System Pharm."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00019048-199905000-00008","article-title":"Pharmacokinetic and economic evaluation of piperacillin\/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin","volume":"8","author":"Richerson","year":"1999","journal-title":"Infect Dis Clin Pract."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0028-3908(03)00188-6","article-title":"Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins","volume":"45","author":"Sugimoto","year":"2003","journal-title":"Neuropharmacology"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jhin.2011.05.028","article-title":"Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe","volume":"79","author":"Pluss-Suard","year":"2011","journal-title":"J Hosp Infect."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmi.2019.06.028","article-title":"Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study","volume":"26","author":"Boschung-Pasquier","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jiac.2021.02.020","article-title":"Using precision dosing to minimize cefepime-induced neurotoxicity: the challenge of targets","volume":"27","author":"Al-Shaer","year":"2021","journal-title":"J Infect Chemother."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0897190015608503","article-title":"Probable nonconvulsive status epilepticus with the use of high-dose continuous infusion ceftazidime","volume":"29","author":"Collins","year":"2016","journal-title":"J Pharm Pract."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-016-0048-y","article-title":"Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study","volume":"17","author":"Descombes","year":"2016","journal-title":"BMC Pharmacol Toxicol."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/FTD.0000000000000786","article-title":"Neurotoxicity despite a renal function-adjusted cefepime regimen: a case study","volume":"42","author":"Engalenc","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jiac.2019.10.006","article-title":"A case of recovery from aphasia following dose reduction of cefepime by bayesian prediction-based therapeutic drug monitoring","volume":"26","author":"Oda","year":"2020","journal-title":"J Infect Chemother."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti-infective Ther."},{"issue":"suppl ment_1","key":"R77-20250603","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/FTD.0b013e3181e60ca6","article-title":"Prospective determination of serum ceftazidime concentrations in intensive care units","volume":"32","author":"Aubert","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00548-10","article-title":"Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis","volume":"55","author":"Connor","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/FTD.0b013e3181ea3e8a","article-title":"Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development","volume":"32","author":"Norris","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0924-8579(02)00020-1","article-title":"Can PK\/PD be used in everyday clinical practice","volume":"19","author":"Scaglione","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an intensive care unit day: the contribution of mechanical ventilation","volume":"33","author":"Dasta","year":"2005","journal-title":"Crit Care Med."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12913-020-05133-5","article-title":"Mechanical ventilation and the daily cost of ICU care","volume":"20","author":"Kaier","year":"2020","journal-title":"BMC Health Serv Res."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","article-title":"Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia","volume":"21","author":"McNabb","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"suppl ment_1","key":"R87-20250603","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among enterobacteriaceae isolates in 20 Years of the SENTRY antimicrobial surveillance program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"ofab387","DOI":"10.1093\/ofid\/ofab387","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC \u03b2-lactamase\u2013producing Enterobacter spp, Citrobacter freundii, Morganella morganii, providencia spp, or Serratia marcescens: a pilot multicenter randomized controlled trial (MERINO-2)","volume":"8","author":"Stewart","year":"2021","journal-title":"Open Forum Infect Dis."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"R90-20250603","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.663033","article-title":"High prevalence of extended-spectrum beta-lactamases in Escherichia coli strains collected from strictly defined community-acquired urinary tract infections in adults in China: a multicenter prospective clinical microbiological and molecular study","volume":"12","author":"Jia","year":"2021","journal-title":"Front Microbiol."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13613-019-0622-8","article-title":"Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria","volume":"10","author":"Kothekar","year":"2020","journal-title":"Ann Intensive Care"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jcpt.13369","article-title":"Meropenem use and therapeutic drug monitoring in clinical practice: a literature review","volume":"46","author":"Steffens","year":"2021","journal-title":"J Clin Pharm Ther."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","article-title":"Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients","volume":"26","author":"Gatti","year":"2022","journal-title":"Crit Care"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/antibiotics9030131","article-title":"Therapeutic drug monitoring of meropenem and piperacillin in critical illness-experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1136\/ejhpharm-2018-001713","article-title":"Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients","volume":"27","author":"Schoenenberger-Arnaiz","year":"2020","journal-title":"Eur J Hosp Pharm."},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients","volume":"41","author":"Fournier","year":"2015","journal-title":"Burns"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"e00794-17","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R100-20250603","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96744-3","article-title":"Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study","volume":"11","author":"Liebchen","year":"2021","journal-title":"Sci Rep."},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/cc11679","article-title":"Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation","volume":"16","author":"Shekar","year":"2012","journal-title":"Crit Care"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2014.11.005","article-title":"\u03b2-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: a case\u2013control study","volume":"45","author":"Donadello","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/microorganisms9061310","article-title":"Meropenem pharmacokinetics and target attainment in critically ill patients are not affected by extracorporeal membrane oxygenation: a matched cohort analysis","volume":"9","author":"Gijsen","year":"2021","journal-title":"Microorganisms"},{"key":"R104-20250603","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.768912","article-title":"Pharmacokinetics and Monte Carlo simulation of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation","volume":"12","author":"Lee","year":"2021","journal-title":"Front Pharmacol."},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis."},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","article-title":"Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole","volume":"9","author":"Moriyama","year":"2015","journal-title":"Curr Fungal Infect Rep."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.02808-13","article-title":"Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis","volume":"58","author":"Liu","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/bcp.14661","article-title":"Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated","volume":"87","author":"Gautier-Veyret","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.hemonc.2017.05.013","article-title":"Complications of hematopoietic stem transplantation: fungal infections","volume":"10","author":"Omrani","year":"2017","journal-title":"Hematology\/Oncology Stem Cel Ther."},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cpt.1012","article-title":"Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults","volume":"104","author":"Mangal","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can J Infect Dis Med Microbiol."},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1093\/jac\/dkv224","article-title":"Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML","volume":"70","author":"Mason","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2146\/ajhp120599","article-title":"Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants","volume":"70","author":"Mauskopf","year":"2013","journal-title":"Am J Health-System Pharm."},{"key":"R120-20250603","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13148","article-title":"Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant","volume":"21","author":"Walker","year":"2019","journal-title":"Transpl Infect Dis."},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/myc.13189","article-title":"The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain","volume":"64","author":"Azanza","year":"2021","journal-title":"Mycoses"},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden","volume":"19","author":"Floros","year":"2019","journal-title":"BMC Infect Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:22:43Z","timestamp":1748971363000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001067","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"2022-08-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}